Latest From BioVentrix Inc.
Start-Up Spotlight: BioVentrix Expects Revivent TC Heart Failure Device To Succeed Where Others Failed
Two-year data from a European trial showed BioVentrix’s Revivent TC system significantly reduces left-ventricular volume and improves left-ventricular function in patients with heart failure following a myocardial infarction. The company expects to complete a US pivotal trial of the device in 2021 and launch the device in the US with funding from a planned initial public offering.
BioVentrix Inc. has its sights set on US market approval for its hybrid transthoracic-endovascular Revivent-TC system, a unique device that enables a minimally invasive approach to treating patients who develop ischemic heart failure following a heart attack.
Despite contraction in the number of funds and VC firms investing in life sciences, 2013 was a strong year for private investing in medtech, with private investors putting $2.54 million into 129 medical device deals, according to Informa’s Strategic Transactions. Looking at where investors placed their money revealed some emerging trends.
Recent executive-level company changes and promotions in the medical device and diagnostics industries.
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Therapeutic Areas
- CHF Technologies Inc.
- North America
- Parent & Subsidiaries
- BioVentrix Inc.
- Senior Management
Ken Miller, Pres. & CEO
William Abbott, CFO
Lon S Annest, MD, CMO
Kevin Van Bladel, VP, R&D
David Schickling, VP, Sales & Mktg.
Serjan D Nikolic, PhD, VP, Therapy Dev.
- Contact Info
Phone: (925) 830-1000
12647 Alcosta Blvd.
San Ramon, CA 94583
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.